PT  - JOURNAL ARTICLE
AU  - Kentaro Tojo
AU  - Natsuhiro Yamamoto
AU  - Nao Tamada
AU  - Takahiro Mihara
AU  - Miyo Abe
AU  - Mototsugu Nishii
AU  - Ichiro Takeuchi
AU  - Takahisa Goto
TI  - Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19
AID  - 10.1101/2022.01.23.22269723
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.23.22269723
4099  - http://medrxiv.org/content/early/2022/04/29/2022.01.23.22269723.short
4100  - http://medrxiv.org/content/early/2022/04/29/2022.01.23.22269723.full
AB  - Background Acute respiratory distress syndrome (ARDS) with COVID-19 is aggravated by hyperinflammatory responses even after the peak of viral load has passed; however, its underlying mechanisms remain unclear. Alveolar epithelial injury is reported to be a very early event in ARDS with COVID-19. Herein, we assessed whether necrosis of alveolar epithelial cells and subsequent releases of damage associated molecular patterns (DAMPs) at an early disease stage aggravates ARDS with COVID-19Methods We analyzed the levels of cytokeratin18-M65, an epithelial total cell death marker; CK18-M30, an epithelial apoptosis-specific marker; and HMGB-1, one of the DAMPs released from necrotic cells, in patients with COVID-19 with and without ARDS and healthy adults, in addition to the circulating alveolar epithelial and endothelial injury markers, namely sRAGE, angiopoietin-2, and surfactant protein-D. Molecular mechanisms of alveolar epithelial cell death and effects of neutralization on alveolar tissue injury were assessed using a mouse model mimicking COVID-19-induced ARDS.Results COVID-19-induced ARDS was characterized by the elevation of sRAGE, an epithelial injury marker, at a very early disease stage. Although both serum levels of CK18-M65 and CK18-M30 were elevated in COVID-19-induced ARDS, the median CK18-M30/M65 ratio, an indicator of the fraction of apoptosis among total epithelial cell death, was 31.5% in serum from COVID-19 patients with ARDS, a value significantly lower than that of non-ARDS patients or healthy subjects. Moreover, the median M30/M65 ratio in bronchoalveolar lavage fluid (BALF) in COVID-19-induced ARDS was 27.8%, indicating that alveolar epithelial cell death is mainly caused by necrosis. Serum levels of HMGB-1 were also significantly elevated in ARDS versus non-ARDS patients. In a mouse model mimicking COVID-19-induced ARDS, the ratio of CK18-M30 to a total epithelial cell death marker in BALF was also lower than that in control subjects. Moreover, the alveolar epithelial cell necrosis involved two forms of programmed necrosis: necroptosis and pyroptosis. Finally, neutralization of HMGB-1 attenuated alveolar tissue injury in the mouse model.Conclusions Necrosis, including necroptosis and pyroptosis, seems to be the primary form of alveolar epithelial cell death and subsequent release of DAMPs is a potential driver of COVID-19-induced ARDS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly supported by AMED under Grant Number JP20he0522001 and JSPS KAKENHI Grant Number 21K16575, and Grant for 2020-2021 Research Development Fund of Yokohama City University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yokohama City University Hospital institutional review boardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.ARDSAcute respiratory distress syndromeANGangiopoietinBALFbronchoalveolar lavage fluidCOVID-19coronavirus disease 2019CKcytokeratinDAMPsdamage-associated molecular patternsELISAenzyme-linked immunosorbent assayHMGBhigh mobility group boxLPSlipopolysaccharidePVDFpolyvinylidene fluoridesRAGEreceptors for advanced glycation end productsSARS-CoV-2severe acute respiratory syndrome coronavirus 2SPsurfactant protein